指南与共识肝病

代谢功能障碍与酒精相关性肝病专家共识德尔菲小组:临床实践中的机遇与挑战

An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice.
指南 / 共识 · Clin Gastroenterol Hepatol · 2025-04-30

该德尔菲共识由10个国家28名专家通过改良德尔菲流程(共识阈值≥80%)制定,针对代谢功能障碍与酒精相关性肝病(MetALD)的临床评估与管理形成28条共识声明,强调酒精摄入量化、客观生物标志物、戒酒后再评估代谢风险与非侵入性检查,并推荐多学科综合管理。

要点

  • 推荐使用经验证问卷量化酒精摄入,并使用磷脂酰乙醇等客观生物标志物。
  • 建议戒酒一段时间后重新评估代谢危险因素和肝病,以区分肝损伤的主要驱动因素。
  • 推荐非侵入性检查评估肝病严重程度,不推荐常规肝活检除非怀疑其他诊断。

核心结论

  • 该德尔菲共识为MetALD的临床评估与管理提供了明确推荐,以应对该疾病带来的独特挑战。

研究设计与样本

  • 采用改良德尔菲流程,包括2轮调查,专家小组由来自4大洲10个国家的28名专家组成,预设共识标准为同意率≥80%。

主要发现

  • 专家组就28条声明达成共识。
  • 推荐对疑似MetALD患者进行全面评估,包括使用经验证问卷量化酒精摄入和使用磷脂酰乙醇等客观酒精使用生物标志物。
  • 强调戒酒一段时间后重新评估代谢危险因素和肝病,以区分肝损伤的主要驱动因素。
  • 推荐非侵入性检查评估肝病严重程度,常规肝活检被认为不必要,除非怀疑其他诊断。
  • 综合管理策略应涉及多学科照护,聚焦生活方式调整、减少或停止饮酒、减重和运动。

关键数值与推荐

  • 共识阈值定义为同意率≥80%。
  • 专家组就28条声明达成共识。

临床怎么用

  • 临床评估疑似MetALD时应使用经验证问卷量化酒精摄入,并使用磷脂酰乙醇等客观生物标志物。
  • 应在戒酒一段时间后重新评估代谢危险因素和肝病,以区分肝损伤的主要驱动因素。
  • 应使用非侵入性检查评估肝病严重程度,不推荐常规肝活检除非怀疑其他诊断。
  • 管理应采用多学科照护,聚焦生活方式调整、减少或停止饮酒、减重和运动。

局限性

  • 专家组识别出显著的知识空白,倡导标准化研究方案、纵向研究、探索病理生理机制以指导精准医学方法,以及验证用于识别MetALD的定量酒精生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction- and alcohol-associated liver disease (MetALD) is a recently defined entity for individuals with liver steatosis, metabolic dysfunction, and increased alcohol intake. However, the current definition of MetALD poses multiple challenges in clinical practice and research. In this Delphi consensus, we provide practical recommendations for the clinical assessment and management of MetALD to address current clinical challenges in MetALD. METHODS: We used a modified Delphi process, including 2 surveys involving a panel of 28 experts from 10 countries spanning 4 continents. We predefined consensus as requiring an ≥80% agreement. RESULTS: The panel reached consensus on 28 statements. Recommendations emphasize the importance of a comprehensive assessment of patients with presumed MetALD, including the quantification of alcohol intake using validated questionnaires and the use of objective biomarkers of alcohol use, such as phosphatidylethanol. The need to reassess metabolic risk factors and liver disease after a period of alcohol abstinence was highlighted to distinguish the primary driver of liver injury. Noninvasive tests were recommended to assess liver disease severity, whereas routine liver biopsy was deemed unnecessary unless other diagnoses were suspected. Comprehensive management strategies should involve multidisciplinary care focusing on lifestyle modifications, alcohol reduction or cessation, weight loss, and exercise. Finally, the panel identified significant gaps in knowledge, advocating for standardized research protocols, longitudinal studies, exploration of pathophysiological mechanisms to inform precision medicine approaches, and the validation of quantitative alcohol biomarkers for identifying MetALD. CONCLUSIONS: This Delphi consensus provides clear recommendations for the clinical assessment and management of MetALD, addressing the unique challenges posed by this condition.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Diaz LA, Ajmera V, Arab JP, et al. An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice. Clin Gastroenterol Hepatol. 2025. PMID: 40315973. doi:10.1016/j.cgh.2025.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。